{'52WeekChange': 0.42249238,
 'SandP52WeekChange': 0.0644362,
 'address1': '75 Park Plaza',
 'address2': '4th Floor',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 4.68,
 'askSize': 900,
 'averageDailyVolume10Day': 384437,
 'averageVolume': 541426,
 'averageVolume10days': 384437,
 'beta': 1.517086,
 'beta3Year': None,
 'bid': 4.68,
 'bidSize': 1400,
 'bookValue': -1.304,
 'category': None,
 'circulatingSupply': None,
 'city': 'Boston',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 4.89,
 'dayLow': 4.89,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': 11.845,
 'enterpriseValue': 270840960,
 'exDividendDate': 1414713600,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 4.8645716,
 'fiftyTwoWeekHigh': 5.89,
 'fiftyTwoWeekLow': 2.5,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 37040505,
 'forwardEps': -0.59,
 'forwardPE': -7.9322033,
 'fromCurrency': None,
 'fullTimeEmployees': 101,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.09806,
 'heldPercentInstitutions': 0.54846,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1414713600,
 'lastSplitFactor': '1:12',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/paratekpharma.com',
 'longBusinessSummary': 'Paratek Pharmaceuticals, Inc., a commercial-stage '
                        'biopharmaceutical company, focuses on the development '
                        'and commercialization life-saving therapies for '
                        'life-threatening diseases or other public health '
                        'threats for civilian, government, and military use. '
                        'Its lead product candidates include NUZYRA, a '
                        'once-daily oral and intravenous broad-spectrum '
                        'antibiotic for the treatment of adult patients with '
                        'community-acquired bacterial pneumonia and acute '
                        'bacterial skin and skin structure infections caused '
                        'by susceptible pathogens; and SEYSARA, a tetracycline '
                        'designed for the treatment of moderate to severe acne '
                        'vulgaris. The company has license and collaboration '
                        'agreements with Zai Lab (Shanghai) Co., Ltd. and '
                        'Allergan plc; license agreement with Tufts University '
                        'to develop and commercialize products for the '
                        'treatment or prevention of bacterial or microbial '
                        'diseases, or medical conditions; and cooperative '
                        'research and development agreement with the U.S. Army '
                        'Medical Research Institute of Infectious Diseases to '
                        'study omadacycline against pathogenic agents causing '
                        'infectious diseases. Paratek Pharmaceuticals, Inc. '
                        'was founded in 1996 and is headquartered in Boston, '
                        'Massachusetts.',
 'longName': 'Paratek Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 201857760,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_1267824',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -120797000,
 'nextFiscalYearEnd': 1640908800,
 'open': 4.89,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 0.02,
 'phone': '617 807 6600',
 'previousClose': 4.87,
 'priceHint': 4,
 'priceToBook': None,
 'priceToSalesTrailing12Months': 8.827856,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 4.89,
 'regularMarketDayLow': 4.89,
 'regularMarketOpen': 4.89,
 'regularMarketPreviousClose': 4.87,
 'regularMarketPrice': 4.89,
 'regularMarketVolume': 230428,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 43132000,
 'sharesPercentSharesOut': 0.091400005,
 'sharesShort': 3942723,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 3624986,
 'shortName': 'Paratek Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.096,
 'shortRatio': 6.67,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'PRTK',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -3.44,
 'twoHundredDayAverage': 4.17741,
 'volume': 230428,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://paratekpharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02116'}